FCF Healthcare & Life Sciences Venture Capital Monitor - Europe - 06/2025 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 06/2024”.

The Monitor is a monthly published overview of venture capital trends in the European Healthcare & Life Sciences sector.

As of the end of June 2025 we identified the following current VC trends in Europe:

• Total Healthcare & Life Sciences funding volume reached EUR 6,109m
• Funding volume is now 33% higher than last year, a sharp increase in funding volume vs. 2024
• Biotech/Pharma received 40% of the total investment volume (EUR 2,426m) with metabolic disorders (including Diabetes, Obesity) being the leading indication (23%)
• In June, Juvenescence (Ireland) secured the highest transaction volume with EUR 132m, followed by SpliceBio (Switzerland) with EUR 119m and Draig Therapeutics (Great Britain) with EUR 103m
• GV (United States) is the most active investor (by deal volume in 2025), followed by Alphabet (United States) and Thrive Capital (United States)

To access the full report, please click here.